$706 Million is the total value of Vivo Capital, LLC's 34 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CDXS | Codexis, Inc. | $33,603,000 | +31.7% | 3,054,825 | 0.0% | 4.76% | -12.9% | |
| APLS | Apellis Pharmaceuticals, Inc. | $32,233,000 | +1.9% | 1,457,834 | 0.0% | 4.57% | -32.6% | |
| VRNA | Verona Pharma Plcads | $29,859,000 | +68.5% | 1,492,951 | 0.0% | 4.23% | +11.4% | |
| ACRS | Aclaris Therapeutics | $28,859,000 | -29.0% | 1,647,214 | 0.0% | 4.09% | -53.0% | |
| Nabriva Therapeutics Plc | $20,493,000 | -15.9% | 4,074,190 | 0.0% | 2.90% | -44.4% | ||
| AMRS | Amyris, Inc. | $18,911,000 | +78.4% | 2,826,711 | 0.0% | 2.68% | +18.0% | |
| EIGR | Eiger BioPharmaceuticals | $17,644,000 | -29.4% | 1,791,257 | 0.0% | 2.50% | -53.3% | |
| KDMN | Kadmon Holdings (KDMN) | $14,167,000 | +17.4% | 3,333,333 | 0.0% | 2.01% | -22.4% | |
| SELB | Selecta Biosciences, Inc. | $11,405,000 | +3.9% | 1,119,189 | 0.0% | 1.62% | -31.3% | |
| SLNO | Soleno Therapeutics, Inc. | $7,313,000 | +0.7% | 4,033,534 | 0.0% | 1.04% | -33.4% | |
| AUPH | Aurinia Pharmaceuticals Inc. | $6,297,000 | +14.6% | 1,213,290 | 0.0% | 0.89% | -24.2% | |
| SRRA | Sierra Oncology, Inc | $5,047,000 | -44.5% | 2,438,270 | 0.0% | 0.72% | -63.3% | |
| RGNX | Regenxbio Inc. | $4,907,000 | -10.2% | 164,403 | 0.0% | 0.70% | -40.6% | |
| FOMX | Foamix Pharmaceuticals Ltd. | $4,386,000 | -14.7% | 855,000 | 0.0% | 0.62% | -43.6% | |
| ZGNX | Zogenix, Inc. | $4,205,000 | 0.0% | 105,000 | 0.0% | 0.60% | -33.9% | |
| AGRX | Agile Therapeutics, Inc. | $3,891,000 | -4.5% | 1,513,975 | 0.0% | 0.55% | -36.8% | |
| KALV | KalVista Pharmaceuticals, Inc. | $2,847,000 | -2.8% | 300,325 | 0.0% | 0.40% | -35.7% | |
| TRVN | Trevena, Inc. | $2,834,000 | +2.5% | 1,728,000 | 0.0% | 0.40% | -32.3% | |
| AKTX | Akari Therapeutics Plcadr | $629,000 | -58.0% | 345,850 | 0.0% | 0.09% | -72.3% | |
| SLNOW | Soleno Therapeutics, Inc.warrant | $23,000 | -14.8% | 188,772 | 0.0% | 0.00% | -50.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 29 | Q3 2023 | 33.5% |
| CODEXIS INC | 29 | Q3 2023 | 8.0% |
| ASCENDIS PHARMA A/S | 25 | Q3 2022 | 24.0% |
| KALVISTA PHARMACEUTICALS INC | 25 | Q3 2023 | 3.9% |
| Verona Pharma PLC ADR | 24 | Q3 2023 | 7.6% |
| AMYRIS INC | 23 | Q3 2023 | 8.8% |
| EIGER BIOPHARMACEUTICALS INC | 23 | Q1 2022 | 8.7% |
| Zai Lab Ltd ADR | 22 | Q3 2023 | 1.8% |
| Arrowhead Pharmaceuticals Inc | 21 | Q3 2023 | 6.9% |
| HOMOLOGY MEDICINES INC | 21 | Q3 2023 | 3.7% |
View Vivo Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SINOVAC BIOTECH LTDSold out | August 27, 2018 | 0 | 0.0% |
View Vivo Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-22 |
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-08 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Vivo Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.